

*Amendments*

*In the Specification:*

Please substitute the paragraph immediately below the title "Cancer Treatment" at page 1 with the following paragraph:

The present application is a continuation of the international application, PCT/GB99/02727, filed August 18, 1999, and published in English as WO 00/10590 on March 2, 2000, which claims priority benefit to Great Britain applications GB 9818023.5, filed August 18, 1998 and GB 9820000.9, filed September 14, 1998. The full disclosures of each of these applications is herein incorporated by reference.

*In the Claims:*

Please replace pending claims 3-6 and 8 with the following claims 3-6 and 8:

3. (Once amended) A method as claimed in claim 1 wherein the angiotensin is angiotensin-II.

4. (Once amended) A pharmaceutical composition to treat or prevent metastasis of cancer cells comprising angiotensin and an excipient or carrier.

5. (Once amended) The pharmaceutical composition of claim 4 adopted for oral, rectal, nasal, topical, vaginal, or parenteral administration.

6. (Once amended) The pharmaceutical composition of claim 5, wherein the parenteral administration is subcutaneous, intramuscular, intravenous, or intradermal.

8. (Once amended) A pharmaceutical composition to induce the expression of B<sub>1</sub> integrin molecules in cancer cells comprising angiotensin and an excipient or carrier.

Please add the following new claims:

9. (New) The pharmaceutical composition of claim 8 adopted for oral, rectal, nasal, topical, vaginal, or parenteral administration.

10. (New) The pharmaceutical composition of claim 9, wherein the parenteral administration is subcutaneous, intramuscular, intravenous, or intradermal.

11. (New) The pharmaceutical composition of claim 4 wherein said angiotensin is angiotensin-II.

12. (New) The pharmaceutical composition of claim 8 wherein said angiotensin is angiotensin-II.

13. (New) The method of claim 7 wherein said angiotensin is angiotensin-II.